New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 12 at 11 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:23 EDTOXGNOXiGENE says fosbretabulin, OXi4503 programs 'moving forward as planned'
Subscribe for More Information
16:21 EDTOXGNOXiGENE reports Q1 EPS (13c), two estimates (13c)
Subscribe for More Information
07:46 EDTMVISMicrovision reports Q1 EPS (9c), consensus 2c
Reports Q1 revenue $901,000, consensus $5.9M
April 24, 2015
10:01 EDTDARAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:24 EDTBJRIBJ's Restaurants outlook still positive after comps miss, says Oppenheimer
After BJ's reported higher than expected EPS but weaker than expected comps, Oppenheimer says that the stock may be in the penalty box for the near-term. However, the firm remains upbeat on what it sees as the company's ongoing margin improvement story and the company's longer-term growth story. It keeps a $56 price target and Outperform rating on the shares.
07:05 EDTDARADara BioSciences initiated with a Buy at H.C. Wainwright
Target $2.
April 23, 2015
16:24 EDTBJRIBJ's Restaurants says restaurant pipeline in 'excellent shape'
BJ's said: "Our 2015 restaurant pipeline remains in excellent shape. We currently have 12 new restaurants under construction and are on track to open at least 15 new restaurants this year. As of this date, we expect to open five new restaurants in the second quarter, including the restaurant which recently opened in Albuquerque, New Mexico, six new restaurants in the third quarter and two new restaurants during the fourth quarter. At the same time, our development team is building a solid pipeline for our fiscal 2016 and 2017 new restaurant openings and we remain committed to our long term annual goal of a 10% increase in operating weeks through new restaurant openings."
16:23 EDTBJRIBJ's Restaurants reports Q1 EPS 36c, consensus 28c
Reports Q1 revenue $225.1M, consensus $225.52M. Comparable restaurant sales increased 3.2%.
10:09 EDTVICLVical management to meet with Roth Capital
Subscribe for More Information
April 22, 2015
09:22 EDTVICLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
06:36 EDTVICLVical awarded $4M contract to manufacture HIV vaccines for clinical evaluation
Subscribe for More Information
April 21, 2015
06:32 EDTVICLVical presents data from Vaxfectin study
Vical announced that Michael McVoy, Professor of Pediatrics at Virginia Commonwealth University, presented data from preclinical studies testing several combinations of Vaxfectin- formulated glycoprotein-B-encoding DNA vaccines for neutralizing antibody responses. Vaxfectin is Vical's novel, proprietary cationic lipid-based adjuvant and is used in CyMVectin, the company's congenital CMV vaccine candidate. The studies found that vaccines encoding gB provided both fibroblast and epithelial entry neutralizing titers that were comparable to those observed in sera from humans with naturally-acquired CMV infections. The data suggest that CyMVectin has the potential to induce neutralizing antibodies against a broad range of cells.
April 20, 2015
07:06 EDTVICLVical management to meet with Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use